

UGT8 antibody (Center)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP11630c

Specification

UGT8 antibody (Center) - Product Information

Application	WB, IHC-P,E
Primary Accession	Q16880
Other Accession	Q09426 , Q64676 , NP_001121646.1 , NP_003351.2
Reactivity	Human, Mouse
Predicted	Rat
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Antigen Region	366-393

UGT8 antibody (Center) - Additional Information

Gene ID 7368

Other Names

2-hydroxyacylsphingosine 1-beta-galactosyltransferase, Ceramide UDP-galactosyltransferase, Cerebroside synthase, UDP-galactose-ceramide galactosyltransferase, UGT8, CGT, UGT4

Target/Specificity

This UGT8 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 366-393 amino acids from the Central region of human UGT8.

Dilution

WB~~1:1000
IHC-P~~1:10~50
E~~Use at an assay dependent concentration.

Format

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

UGT8 antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.

UGT8 antibody (Center) - Protein Information

Name UGT8 ([HGNC:12555](#))

Synonyms CGT, UGT4

Function Catalyzes the transfer of galactose to ceramide, a key enzymatic step in the biosynthesis of galactocerebrosides, which are abundant sphingolipids of the myelin membrane of the central nervous system and peripheral nervous system (PubMed:[9125199](#)). Galactosylates both hydroxy- and non-hydroxy fatty acid-containing ceramides and diglycerides (By similarity).

Cellular Location


Membrane; Single-pass membrane protein. Endoplasmic reticulum
{ECO:0000250|UniProtKB:Q09426}

UGT8 antibody (Center) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


UGT8 antibody (Center) - Images



UGT8 antibody (Center) (Cat. #AP11630c) western blot analysis in mouse cerebellum tissue lysates (35ug/lane). This demonstrates the UGT8 antibody detected the UGT8 protein (arrow).



All lanes : Anti-UGT8 antibody (Center) at 1:1000 dilution Lane 1: U-87 MG whole cell lysate Lane 2: HeLa whole cell lysate Lysates/proteins at 20 μ g per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 61 kDa Blocking/Dilution buffer: 5% NFDM/TBST.



UGT8 antibody (Center) (Cat. #AP11630c) immunohistochemistry analysis in formalin fixed and paraffin embedded human brain tissue followed by peroxidase conjugation of the secondary antibody and DAB staining. This data demonstrates the use of UGT8 antibody (Center) for immunohistochemistry. Clinical relevance has not been evaluated.

UGT8 antibody (Center) - Background

Galactocerebrosides are abundant sphingolipids of the myelin membrane of the central nervous system and peripheral nervous system and are also present in small amounts in kidney. The key enzymatic step in the biosynthesis of galactocerebrosides consists of the transfer of galactose to ceramide catalyzed by UDP-galactose ceramide galactosyltransferase (CGT, EC 2.4.1.45). The enzyme encoded by the CGT gene is the first involved in complex lipid biosynthesis in the myelinating oligodendrocyte. [supplied by OMIM].

UGT8 antibody (Center) - References

Dziecedil Giel, P., et al. Br. J. Cancer 103(4):524-531(2010)
Kalsi, G., et al. Hum. Mol. Genet. 19(12):2497-2506(2010)

Ross, C.J., et al. Nat. Genet. 41(12):1345-1349(2009)

Ruckhaberle, E., et al. J. Cancer Res. Clin. Oncol. 135(8):1005-1013(2009)

Saito, A., et al. J. Hum. Genet. 54(6):317-323(2009)

UGT8 antibody (Center) - Citations

- [The miR-30 Family Inhibits Pulmonary Vascular Hyperpermeability in the Premetastatic Phase by Direct Targeting of Skp2.](#)